Terms: = Breast cancer AND ABL2, ARG, 27, ENSG00000143322, P42684, ABLL, RP11-177A2_3 AND Clinical Outcome
1090 results:
1. Conditional generative adversarial network driven radiomic prediction of mutation status based on magnetic resonance imaging of breast cancer.
Huang ZH; Chen L; Sun Y; Liu Q; Hu P
J Transl Med; 2024 Mar; 22(1):226. PubMed ID: 38429796
[TBL] [Abstract] [Full Text] [Related]
2. Tumor budding in breast carcinoma: A systematic review and meta-analysis.
Buch A; Khan U; Rathod H; Jain K; Dwivedi A; Rajesh A
J Cancer Res Ther; 2023 Oct; 19(7):1697-1713. PubMed ID: 38376268
[TBL] [Abstract] [Full Text] [Related]
3. Adrenal incidentalomas, cortisol secretion and cancer: is there a real crosstalk?
Herrera-Martínez AD; Román ÁR; Corrales EP; Idrobo C; Ramírez PP; Rojas PM; Lázaro CR; Araujo-Castro M
Front Endocrinol (Lausanne); 2023; 14():1335202. PubMed ID: 38264281
[TBL] [Abstract] [Full Text] [Related]
4. Effectiveness and toxicity of five-fraction prone accelerated partial breast irradiation.
Hardy-Abeloos C; Xiao J; Oh C; Barbee D; Shah B; Maisonet O; Perez C; Adams S; Schnabel F; Axelrod D; Guth A; Karp N; Cahlon O; Gerber N
Breast Cancer Res Treat; 2024 Apr; 204(3):485-495. PubMed ID: 38183516
[TBL] [Abstract] [Full Text] [Related]
5. Comparison of Circulating Tumor DNA Assays for Molecular Residual Disease Detection in Early-Stage Triple-Negative breast cancer.
Coakley M; Villacampa G; Sritharan P; Swift C; Dunne K; Kilburn L; Goddard K; Pipinikas C; Rojas P; Emmett W; Hall P; Harper-Wynne C; Hickish T; Macpherson I; Okines A; Wardley A; Wheatley D; Waters S; Palmieri C; Winter M; Cutts RJ; Garcia-Murillas I; Bliss J; Turner NC
Clin Cancer Res; 2024 Feb; 30(4):895-903. PubMed ID: 38078899
[TBL] [Abstract] [Full Text] [Related]
6. A Phase I/II Study of GSK525762 Combined with Fulvestrant in Patients with Hormone Receptor-positive/HER2-negative Advanced or Metastatic breast cancer.
Cescon DW; Hilton J; Morales Murilo S; Layman RM; Pluard T; Yeo B; Park IH; Provencher L; Kim SB; Im YH; Wyce A; Krishnatry AS; Hicks K; Zhang Q; Barbash O; Khaled A; Horner T; Dhar A; Oliveira M; Sparano JA
Clin Cancer Res; 2024 Jan; 30(2):334-343. PubMed ID: 37992310
[TBL] [Abstract] [Full Text] [Related]
7. TJP3 promotes T cell immunity escape and chemoresistance in breast cancer: a comprehensive analysis of anoikis-based prognosis prediction and drug sensitivity stratification.
Chaojun L; Pengping L; Yanjun L; Fangyuan Z; Yaning H; Yingbo S; Qi C; Hui L
Aging (Albany NY); 2023 Nov; 15(22):12890-12906. PubMed ID: 37950731
[TBL] [Abstract] [Full Text] [Related]
8. Vascular endothelial growth factor (VEGF) -A, -C and VE-cadherin as potential biomarkers in early breast cancer patients.
Milovanović J; Vujasinović T; Todorović-Raković N; Greenman J; Hranisavljević J; Radulovic M
Pathol Res Pract; 2023 Dec; 252():154923. PubMed ID: 37948997
[TBL] [Abstract] [Full Text] [Related]
9. Observational analysis of clinical and pathological characteristics and their prognostic impact in Mexican patients with breast cancer: A multi-center study.
Gozalishvilli-Boncheva A; Gonzalez-Espinoza IR; Castro-Ponce A; Bravo-Gutiérrez OA; Juárez-Salazar G; Montes-de-Oca-Moreda RI; Aguirre-Flores E; Coyotl-Huexotl M; Orozco-Luis J; Chiquillo-Domínguez M; Garibay-Díaz JC; Aranda-Claussen JE; Ponce-de-León EA; Sánchez-Sosa S; Sabaté-Fernández M; García-Reyna JC; Cordero-Vargas C; González-Blanco MJ; Aguilar-Priego JM; Sánchez-Fernández NJ; Cortés-García CA; González-Lozada LE; Miguel-Cruz E; Ceja-Utrera FJ; Hernández-Garcia MS; Piña-Vazquez M; Aguilar-Jiménez C
Breast Dis; 2023; 42(1):305-313. PubMed ID: 37807773
[TBL] [Abstract] [Full Text] [Related]
10. clinical and imaging features of interstitial lung disease in cancer patients treated with trastuzumab deruxtecan.
Baba T; Kusumoto M; Kato T; Kurihara Y; Sasaki S; Oikado K; Saito Y; Endo M; Fujiwara Y; Kenmotsu H; Sata M; Takano T; Kato K; Hirata K; Katagiri T; Saito H; Kuwano K
Int J Clin Oncol; 2023 Dec; 28(12):1585-1596. PubMed ID: 37787866
[TBL] [Abstract] [Full Text] [Related]
11. Clinicopathological and prognostic value of TIL and PD L1 in triple negative breast carcinomas.
Uğurluoğlu C; Yormaz S
Pathol Res Pract; 2023 Oct; 250():154828. PubMed ID: 37778126
[TBL] [Abstract] [Full Text] [Related]
12. Real-world evidence of neoadjuvant chemotherapy for breast cancer treatment in a Brazilian multicenter cohort: Correlation of pathological complete response with overall survival.
Antonini M; Mattar A; Bauk Richter FG; Pannain GD; Teixeira MD; Amorim AG; Ferraro O; Guedes Lopes RC; Gebrim LH; Real JM
Breast; 2023 Dec; 72():103577. PubMed ID: 37722319
[TBL] [Abstract] [Full Text] [Related]
13. Combination Organelle Mitochondrial Endoplasmic Reticulum Therapy (COMET) for Multidrug Resistant breast cancer.
Milane LS; Dolare S; Ren G; Amiji M
J Control Release; 2023 Nov; 363():435-451. PubMed ID: 37717658
[TBL] [Abstract] [Full Text] [Related]
14. clinical and prognostic role of sarcopenia based on masticatory muscle index on MR images in patients with extranodal natural killer/T cell lymphoma, nasal type.
Xu T; Li Y; Liu Y; Ning B; Wu H; Wei Y
Ann Hematol; 2023 Dec; 102(12):3521-3532. PubMed ID: 37702822
[TBL] [Abstract] [Full Text] [Related]
15. Pyrotinib plus capecitabine for trastuzumab-resistant, HER2-positive advanced breast cancer (PICTURE): a single-arm, multicenter phase 2 trial.
Cao J; Teng Y; Li H; Zhang L; Ouyang Q; Xie W; Pan Y; Song Z; Ling X; Wu X; Xu J; Li L; Ren L; Wang H; Zhou D; Luo J; Hu X
BMC Med; 2023 Aug; 21(1):300. PubMed ID: 37559142
[TBL] [Abstract] [Full Text] [Related]
16. Feasibility and efficacy of ultrasound-guided high-intensity focused ultrasound of breast fibroadenoma.
Liang M; Zhang Z; Zhang C; Chen R; Xiao Y; Li Z; Li T; Liu Y; Ling L; Xie H; Chen L; Liu X; Wang S; Xia T
Int J Hyperthermia; 2023; 40(1):2240548. PubMed ID: 37544652
[TBL] [Abstract] [Full Text] [Related]
17. The mutational landscape of a US Midwestern breast cancer cohort reveals subtype-specific cancer drivers and prognostic markers.
Vellichirammal NN; Tan YD; Xiao P; Eudy J; Shats O; Kelly D; Desler M; Cowan K; Guda C
Hum Genomics; 2023 Jul; 17(1):64. PubMed ID: 37454130
[TBL] [Abstract] [Full Text] [Related]
18. Pathological complete response rate and clinical outcome after neoadjuvant therapy of HER2-low breast cancer: A National cancer Database Analysis.
Zhong G; Song D; Lou W; Wei B; Chen Y; Cui H; Hu J; Dong H; Chen J; Dai Z
Eur J Surg Oncol; 2023 Nov; 49(11):106970. PubMed ID: 37365055
[TBL] [Abstract] [Full Text] [Related]
19. Prognostic Power of Nutrition-Inflammation Indicators in Patients With breast cancer.
Zhang XW; Ge YZ; Song MM; Ruan GT; Xie HL; Hu CL; Shi HP
Clin Breast Cancer; 2023 Jul; 23(5):e312-e321. PubMed ID: 37236827
[TBL] [Abstract] [Full Text] [Related]
20. Bioinformatics identification and validation of aging‑related molecular subtype and prognostic signature in breast cancer.
Li J; Gao F; Su J; Pan T
Medicine (Baltimore); 2023 May; 102(19):e33605. PubMed ID: 37171324
[TBL] [Abstract] [Full Text] [Related]
[Next]
